LinkSolution selected for Jeonbuk Technopark biotech R&D program to build multi-nozzle 3D bioprinting platform for spinal cord nerve regeneration

LinkSolution, a Korean industrial 3D-printing company that listed on KOSDAQ in 2025 under the technology special-listing track, said on July 28 it has been selected for Jeonbuk Technopark's advanced biotech R&D support program to develop a multi-nozzle 3D bioprinting platform targeting spinal cord nerve regeneration. LinkSolution leads the consortium as the managing institution, with Wonkwang University developing the neural-regeneration bioink and Hallym University running preclinical evaluation, including a porcine spinal cord injury model; the project runs through May 2029. The platform combines LinkSolution's existing MicroDispenser hydrogel 3D printers and Monopump-series extrusion systems with new multi-nozzle capability to print microchannel scaffolds that guide axon regrowth in a fixed direction, loaded with bioinks carrying nerve-regeneration growth factors and therapeutic agents.

The move extends LinkSolution beyond its core industrial hardware business, which spans mobility, aerospace, defense, and medical AM systems, into biofabrication tooling, leaning on its own patent portfolio in multi-nozzle heads, hydrogel dispensing, and bioprinter nozzle tips as the technical entry point. Multi-material extrusion, printing several bioinks with different mechanical and biological properties in a single structure, is the enabling capability for building scaffolds complex enough to direct nerve cell growth rather than just support it. This is a preclinical-stage, multi-year program with no near-term commercial revenue attached; the real test is whether the porcine model shows measurable nerve regeneration and safety, not the printer specifications themselves.

For a company simultaneously building a 3D-printing foundry in Daejeon, the program is a bet on diversifying into regenerative medicine tooling, a slower but potentially higher-margin adjacency to its industrial hardware base, with LinkSolution positioning the platform for eventual expansion into peripheral nerve and broader central nervous system applications.